Two Things are of interest.
1.NR2F6--->Applicatble to canine/feline cancer. This is what C. Ichim brought to the party.
Dr. Ichim stated, "I am extremely excited about having the opportunity to apply my knowledge of cancer stem cells to treating leukemia in cats and cancer in dogs...7/16/14.
"The findings of novel candidate sequences to improve gene silencing of NR2F6 is a fundamental advancement in our work towards biologically treating cancer," said Dr. Thomas Ichim, Chief Scientific Officer...1/8/15.
"NR2F6 (EAR-2) is a novel leukemia and MDS oncogene, over-expressed in patients, that inhibits hematopoietic differentiation and blocks erythropoietic differentiation at the proerythrocyte stage.....5/5/15.
2. Regen approached by NUMEROUS ENTITIES. Could be HUGE gamechanger for the trio.
A Company Spokesperson noted that, as a result of these presentations, Regen has been approached by numerous entities working in the area of MDS and Leukemia that are interested in possible future collaborations, co-development and other potential involvements with the Company....5/5/15.
